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Duchenne Muscular Dystrophy is a degenerative muscle disease that is 
characterized by the breakdown of skeletal muscle as a result of membrane instability. A 
mutation in the dystrophin gene, one of the largest gene in the human genome, results in a 
complete lack of dystrophin in the membrane of skeletal muscle cells. Damaged muscle 
fibers result in necrosis and promote the formation of fatty, connective tissue. There is 
presently no cure for the disease and treatment primarily consists of long-term steroid 
therapy to slow its progression. Current research involves examining the various 
mechanisms involved in stabilizing membrane proteins in the absence of dystrophin. The 
interactions of the proteins sarcospan and utrophin as well as related glycosyltransferase 
activity are further examined in depth. 
A case study of a 5 year old patient is discussed in order to shed light on the 
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Chapter I: History, Pathophysiology, and Current Research 
Introduction 
Duchenne Muscular Dystrophy (DMD) is a degenerative X-linked recessive 
disease that affects 1 in 3600 male infants. DMD results from mutations in the Xp21 
gene, a gene which codes for the protein dystrophin. Dystrophin is a cytoplasmic protein 
that provides structural support to muscle cells by stabilizing the dystrophin-associated 
glycoprotein complex (DAGC), a transmembrane complex consisting of integral and 
peripheral membrane proteins which are responsible for connecting the cytoskeleton of 
muscle fibers to the extracellular matrix, thereby maintaining the integrity of muscle 
cells.  Frameshift mutations within the dystrophin gene result in a complete lack of 
dystrophin in DMD. The absence of dystrophin compromises the integrity of the DAGC 














Symptomology and Epidemiology  
Symptoms of DMD usually appear before the age of 6; they may appear as early 
as 3 years of age. Many infants are found to be unable to crawl or display movement of 
their limbs characteristic of normal muscle development in children. Patients display a 
difficulty in getting up or lying down, as muscle weakness in the hips, thighs, calf 
muscles and pelvic area is representative of the early stages of DMD. Diminished control 
of fine motor skills is also indicative of the disease. A further progression may see 
pseudohypertrophy of calf and shoulder muscles resulting from massive scar tissue. 
DMD patients usually lose their ability to walk and are wheelchair-bound by the age of 
12 (Jennekens, 1991). Deterioration of the back muscles can consequently lead to acute 
scoliosis. A small percentage of patients also display evidence of cognitive impairment 
which result in learning disabilities and an average IQ of 80-85 on the Wechsler Children 
Intelligence Scale (Anderson, 2002). The rate of prevalence of mental impairment in 
DMD patients is approximately 33%. These cognitive deficiencies, however, are not of a 
progressive nature. Breathing difficulties and cardiomyopathy arise in the advance stages 
of DMD when the disease spreads to cardiac and pulmonary tissues, resulting in the 
possible need of assisted ventilation and pacemakers. The average life expectancy of 
DMD patients is 25 years of age. Respiratory or cardiac complications are the eventual 
causes of death. 
Another form of muscular dystrophy, Becker Muscular Dystrophy (BMD), results 
from in-frame mutations within the dystrophin gene. It is a less severe form of muscular 
dystrophy in which degeneration progresses at a slower rate with a later onset of the 
symptoms. The nature of the mutation does not lead to a complete lack of dystrophin; 
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rather, the normal physiological levels of dystrophin are reduced or the dystrophin 
produced is shown to have an irregular structure (England, 1990). Patients with BMD 
typically live twice as long as those with DMD and may even have a normal lifespan.  
 
Diagnosis 
 Creatine Phosphokinase (CK) is an enzyme that catalyzes the reversible 
conversion of creatine to phosphocreatine with the consumption of one ATP. The MM-
CK isoenzyme is specifically abundant in skeletal and cardiac muscle. Elevated CK 
levels are indicative of muscle damage. The creatine phosphokinase test is used to 
diagnose DMD in patients, as there are usually elevated levels of stress in skeletal or 
cardiac muscles (Mendell, 2012). A muscle biopsy stained with dye can further reveal the 
presence, or lack of, dystrophin. An electromyography can also be run to determine 
muscle health and the extent of nerve control of muscles.  
 
Pathophysiology 
The dystrophin gene is the largest in the human genome. Comprising of 
approximately 2.4 million base-pairs, the gene consists of 79 exons and takes over 16 
hours to be transcribed and spliced (Koenig et al, 1987). Although DMD primarily arises 
from large insertions or deletions that cause massive frameshift mutations, small point 
mutations can also contribute to the pathology of the disease. Insertions and deletions 
contribute to approximately 60% of DMD cases while 40% are attributed to smaller point 
mutations (Hoffman, 2001). The massive size of the dystrophin gene complex gives 
opportunity for multiple mutations to occur. The severity of the mutation results in a 
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complete lack of dystrophin and a diminished number of DAGC proteins as well, 
compromising the structural stability provided by the cytoskeleton and extracellular 










Figure 1. The dystrophin-associated glycoprotein complex of a normal muscle cell. 
Dystrophin provides the necessary support by connecting the cytoskeleton to the rest of 
the complex. Absence of dystrophin affects several other proteins within the complex as 
well as their binding capabilities to other proteins and the extracellular matrix (Original 
source:  Nowak, 2004). 
 
The dystrophin protein has several tissue-specific isoforms that arise from 
promoters along the dystrophin gene— the brain, muscle, and Purkinje promoters 
(Makover, 1991).The brain promoter codes for dystrophin expression in the hippocampus 
and cortical neurons while the Pukinje promoter directs dystrophin expression in 
cerebellar Purkinje cells (Górecki, 1992). The muscle promoter drives the primary 
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expression of dystrophin in skeletal muscle and cardiac cells, although the brain promoter 
is also responsible for certain amounts of dystrophin in cardiac muscle (Muntoni, 1995).  
The absence of dystrophin results in the disruption of the DAGC which consists 
of proteins such as dystroglycans, sarcoglycans, integrins and caveolin. Furthermore, the 
lack of dystrophin has shown evidence of a diminished number of other membrane-
associated proteins in the complex that leads to further instability and the disruption of 
cell signaling. A loss of certain surface glycoproteins makes the sarcolemma more 
susceptible to micro-rupturing. The level of sarcalumenin, a luminal Ca2+ binding protein 
in skeletal muscles, is significantly lowered in DMD patients. Sarcalumenin is 
responsible for calcium buffering within the sarcoplasmic reticulum (SR). Compared to 
normal muscles cells, the expression of sarcalumenin is approximately 70% lower in 
diseased muscle fibers (Dowling, 2004). Abnormal clustering of calsequestrin, a calcium-
binding protein responsible for storing calcium in the SR, contributes to the maintenance 
of the Ca2 +concentration gradient. The structural instability disrupts the homeostasis of 
ion activity, leading to increased cytosolic Ca2+ levels as well as damaged luminal Ca2+ 
buffering (Dowling, 2003) as seen in figure 2. The structural instability allows for Ca2+ to 
leak across the membrane to disrupt the extensive signaling pathway within the 
mitochondria, affecting the mechanism of muscle contraction and damaging the muscle 
cells in an induced necrosis. The attempt to repair this damage leads to the formation of 
scar and connective tissue which contributes to the characteristic pseudohypertrophy in 




Figure 2.  Comparison of Ca2+ signaling in normal and dystrophin muscle cells. The 
image on the left shows normal calcium concentrations both inside the SR and in the 
cytosol. The image on the right shows calcium concentrations in dystrophic muscle. The 
SERCA1, C2+-ATPase is assisted by calsequestrin to ease the pumping gradient. Lack of 
calsequestrin in dystrophic muscle interferes with the ATPase activity and causes a 
higher concentration of Ca2+ in the cytosol than in the SR. (Original Source: Solares-
Pérez et al, 2010) 
 
Cognitive impairment associated with DMD results from an absence of 
dystrophin is the brain. The cerebral cortex of the brain plays a prominent role in 
memory, language, thought, in awareness. The deficiency of the protein in the cerebral 
cortex is thought be the primary cause for the development of learning disabilities in 
patients. Additionally, a deficiency in the cerebellum is thought to contribute to the 
pulmonary issues that arise in the later stages of the disease. As stated previously, the 
multiple mutations within the dystrophin gene are thought to contribute to deficit of other 
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proteins involved in maintaining cell structure integrity.  A deficit of glycosyltransferase-
like protein LARGE1 is common in DMD patients. The protein is responsible for the 
glycosylation of the α-dystroglycan complex which promotes the binding of the complex 
to laminin-2 and the extracellular matrix (Brockington et al, 2005). The LARGE protein 
is known to have a high expression in the brain. A lack of LARGE is suspected of 
diminishing the binding capability of α-dystroglycan to laminin and causing white matter 
changes and structural abnormalities in the brain, leading to cognitive impairment 
(Longman et al, 2003). 
Sarcospan, a transmembrane protein, directly associates with utrophin and 
maintains the integrity of the sarcoglycan subcomplex. Spanning the membrane several 
times, it is an anchor for the subcomplex and plays a key role in stabilizing the binding to 
the extracellular matrix and does so by elevating the expression of utrophin (Peter, 2008). 
Utrophin, ubiquitous dystrophin, is a protein found at the neuromuscular junctions of 
normal muscle cells. Its structure is homologous to dystrophin and is important in 
maintaining structural integrity and plays a role in stabilizing the acetylcholine receptor 
clusters (Huh, 2002). During fetal development, utrophin is found in abundance in the 
sarcolemma during muscle differentiation. When the fetus begins to express dystrophin, 
utrophin is replaced and disappears from most all areas except at the aforementioned 
neuromuscular synapses. Utrophin expression is considerably increased in patients with 
DMD, perhaps to compensate for the lack of dystrophin in an attempt to maintain 
structural integrity.   
Advanced stages of DMD patients show signs of respiratory and cardiac failure. 
Degeneration spreads to smooth muscle cells of the diaphragm, decreasing respiratory 
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function. This deterioration affects muscles used in coughing, allowing for bacterial and 
viral growth in the lungs because of an inability to clear lung secretions.  Progressive cell 
death and replacement of conductive tissue by thick, fibrous tissue can result in heart 
disease known as X-linked dilated cardiomyopathy, although this specific 
cardiomyopathy is not very prevalent. Mutations in the muscle isoform of dystrophin 
affect expression in specifically the heart which contributes to the onset of 
cardiomyopathy (Ferlini, 2012). This onset can be exacerbated by the physical inactivity 
of a patient who is wheelchair bound. 
 
Treatment  
 There is currently no cure for DMD. The most successful course of treatment is 
management of the disease with corticosteroids. Prednisone is the primary steroid used to 
slow the progression of the disease and rebuild muscle strength. It has been shown to 
slow the progression of the disease and increase the rate of repair and regeneration. The 
use of corticosteroids has also been shown to enhance lung and cardiac function as well 
as reduce the need for scoliosis surgery (Beytía, 2012). Prednisone, however, is 
associated with a number of side effects including weight gain, hypertension, diabetes 
and skeletal fractures. Deflazacort, a derivative of Prednisone, has diminished side 
effects; however, the corticosteroid is associated with cataracts and is currently 
unavailable in the United States.  
  Physical therapy has shown to be effective in managing muscle strength and 
function. Physical therapy can reduce muscle tightening and built muscle strength. 
Physical inactivity can contribute to the worsening of the disease, especially its 
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progression towards pulmonary and cardiac issues. Cardiomyopathy in DMD usually is 
not associated with heart failure. Even so, with the development of cardiomyopathy, a 24-
hour Holter ECG record is used to continuously monitor heart activity. Ventilation 
support is common when pulmonary issues arise.  
 
Current Research  
 There are many avenues of research being pursued to reach an effective cure. 
Gene replacement therapy of missing dystrophin has yielded unsuccessful results. 
Transduction of cells to induce gene expression of dystrophin yields only localized 
effects; while the injection therapy does successfully induce functioning dystrophin, it 
only does so for muscle cells near the injection site (O’Hara, 2001).  Effective results 
would require massive amounts as well as continual, perhaps life-time, injections to 
transduce cells of a whole muscle to express dystrophin. In response, viral vectors are 
being studied as a systemic delivery method.  
 Other promising research avenues involve the upregulation of certain proteins 
within the DAGC, such as integrin, dystroglycan, utrophin, or sarcospan. Overexpression 
of utrophin may compensate for the lack of dystrophin based on their similarities. An 
upregulation of specific glycosyltransferases may also prove effective in strengthening 
binding to the extracellular matrix by increasing glycosylation activity of certain proteins.  
Increasing expression of these proteins may compensate for the structural instability 
induced by a lack of dystrophin. A therapy that involves overexpression of several of 




Chapter II: Stabilization of the Dystrophin-Associated Glycoprotein Complex 
through the Interaction of Sarcospan and Utrophin and the Enhancement of Intra-
complex Binding via Galgt2 Glycosyltransferase Activity 
 
 
The dystrophin-associated glycoprotein complex (DAGC) is a transmembrane 
complex made up of integral and peripheral membrane proteins. The complex is 
responsible for connecting the cytoskeleton of muscle fibers to the extracellular matrix. 
The lack of dystrophin in DMD patients disrupts the structural stability of the DAGC, 
interrupting protein binding interactions and leading to impaired laminin binding to the 
extracellular matrix, causing the complex to fall apart. It is thought that the lack of 
dystrophin also affects the number of proteins present at the membrane as well as their 
interactions with one another, contributing to an overall weakening of the complex in 
DMD patients. Evidence has shown that expression of utrophin, a protein homologous to 
dystrophin, is upregulated in patients with DMD, perhaps to compensate for the lack of 
dystrophin. Sarcospan, a transmembrane protein, has shown to function as an anchor for 
the complex, interacting directly with utrophin and several sarcoglycans. Its presence is 
integral in stabilizing the dystrogylcan subunits of the complex that directly interact with 
the extracellular matrix via laminin. The strength of this binding interaction is enhanced 
by glycosylation of the dystroglycan subunits. Stabilization of the dystroglycan subunit 
and its interactions with the extracellular matrix can be accomplished by studying the role 
of the utrophin-specific glycosyltransferase activity of Galgt2 in intra-complex and 
laminin binding and by understanding the mechanisms by which sarcospan interacts with 





Utrophin, ubiquitous dystrophin, is found at the neuromuscular junctions of 
normal muscle cells. It plays a key role in stabilizing the utrophin-associated glycoprotein 
complex. Although utrophin is normally replaced with dystrophin during fetal 
development, its expression is altered in DMD. Its presence expands beyond its normal 
place in the neuromuscular junctions and takes the place of dystrophin to reestablish 
structural stability (Matsumura, 1992). In patients with DMD, these elevated utrophin 
levels in absence of dystrophin form a complex analogous to the DAGC, known as the 
utrophin-associated glycoprotein complex (UAGC). However, the naturally elevated 
levels of utrophin in DMD patients cannot halt the pathology of the disease alone. 
 
Sarcospan 
 Utrophin’s ability to stabilize the protein complex is dependent upon the protein 
sarcospan. Sarcospan is a transmembrane protein that is a vital part of the UAGC. It is a 
major component in coordinating adhesion proteins within the complex to the 
extracellular matrix. Sarcospan directly associates with both utrophin and the sarcoglycan 
subcomplex and is important in regulating utrophin levels (Peter, 2008). Sarcospan 
possesses a homology to tetraspanin proteins; it spans the membrane several times to 
anchor the complex to the membrane. It contains four transmembrane domains as well as 
a large extracellular loop (Maecker, 1997). Studies have shown that although the absence 
of dystrophin reduces the expression of sarcospan, the presence of utrophin in the 
neuromuscular junctions retains the expression this anchor protein. Furthermore, the 
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upregulation of utrophin beyond its normal location promotes the elevated expression of 
sarcospan as well (Crosbie et al, 1999). 
The sarcoglycan (SG) subcomplex is composed of four transmembrane 
glycoproteins that each pass through the membrane once. These protein subunits are 
referred to as α-, β-, γ-, and δ-SG (Lim and Cambell, 1998). The alpha-dystroglycan (α-
DG) protein, an extracellular cell-surface protein, is another core component of the 
glycoprotein complex.  α-DG is a receptor which directly interacts with the laminin-2 
component of the extracellular matrix and plays a critical role in binding (Cabrera et al, 
2012). It is associated with the integral membrane protein β-dystroglycan (β-DG) via 
non-covalent interactions. The COOH-terminus of β-DG directly associates with the 
COOH-terminus domain of either dystrophin or utrophin (Jung, 1995). The SGs are 
responsible for coordinating the attachment of α-DG to the cell membrane through their 
direct interactions with β-DG. A mutation in any of these protein subunits can lead to an 
autosomal form of muscular dystrophy (Crosbie et al, 1999).  Without sarcospan, the 
stability of the SGs is compromised, affecting their interactions with the DG complex and 
impairing their role in laminin binding. 
 The expression of sarcospan and its effects on the integrity of the UAGC correlate 
with the level of utrophin expression. This expression is not due to an increase in 
utrophin transcription; in studies of dystrophic mice treated with sarcospan, the levels of 
utrophin mRNA were relatively the same as dystrophic mice not treated with sarcospan, 
despite a measured increase in utrophin levels (Peter et al, 2008). It is thought that 
utrophin transportation through the endoplasmic reticulum and Golgi apparatus is 
augmented by sarcospan, which enhances utrophin expression at the membrane. 
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Furthermore, the tetraspanin nature of sarcospan suggests that its scaffolding ability is 
vital in utrophin stabilization, suggesting that elevated utrophin levels may be due to 
efficient utrophin utilization by sarcospan at the cell membrane. It is interesting to note 
that the addition of sarcospan increases utrophin expression but does not affect 
dystrophin expression, suggesting that the interaction between utrophin and sarcospan is 
quite specific. A deficiency of sarcospan within muscle fibers has shown to have also 
diminished utrophin expression, further fortifying the specificity of their association. 
 
Research and Treatment: The Association between Sarcospan and Utrophin 
 An increase in utrophin or dystrophin expression would seem to be the most 
effective treatment for DMD, and traditionally these proteins have been the main target of 
potential DMD therapies. However, the genetic nature of these proteins proves to be a 
problem in creating viral vectors. The utrophin gene is 900kbp long while dystrophin is 
coded by one of the largest human genes in the genome at 2.4Mbp long (Helliwell, 1992). 
The massive size of these genes makes it difficult to insert them within a viral vector and 
has often resulted in creating shortened or “mini dystrophin” cDNA as a substitute 
(Alameddine, 1994). Although these viral vectors have been shown to alleviate DMD 
pathology, the process is a labored and expensive one. Sarcospan, in contrast, is coded by 
a 1.0 kbp long gene. Its small size gives it an advantage, as it can be more easily 
packaged into viral vectors and introduced within the target cell without the need for size 
modification. Sarcospan’s effect on utrophin expression can be used to provide structural 
stability to the UAGC and slow, if not reverse, the progression of DMD. Although 
utrophin is found to have expanded expression outside the neuromuscular junction in 
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DMD, the upregulation of sarcospan extends the effects of utrophin beyond its normal 
reach and can be detected all throughout the sarcolemma (Peter, 2008).  Overexpression 
of sarcospan delivered via viral vectors would in turn increase utrophin transportation 
within muscle cells and its expression near the cell surface where the absent dystrophin 
should have been.  
 Although elevated expression of sarcospan could prove to be an effective 
treatment, the magnitude of this upregulation must be carefully controlled for several 
reasons. As seen in the diagram of the UAGC (fig 3), sarcospan is firmly embedded 
within the plasma membrane. It is also very closely associated with the sarcoglycan 
subcomplex. A 10-fold overexpression of sarcospan could lead to sarcospan clustering 
into insoluble protein groups at the membrane site (Peter et al, 2007). This physical 
abnormality is shown to disturb the assembly of the UAGC at the membrane and further 
destabilize binding to the extracellular matrix. However, a milder upregulation of 
sarcospan, approximately a 3-fold overexpression, found that levels of proteins within the 
UAGC could be increased without disrupting the structure and binding function of the 
complex (Peter et al, 2007).  As such, increased expression of sarcospan through 
transduction with viral vectors must be carefully regulated to prevent and further 

















  Figure 3. The utrophin-associated glycoprotein complex. The diagram shows the 
tetraspanin-like sarcospan associated with both sarcoglycans and utrophin. Utrophin is 
shown binding to both the actin cytoskeleton and the β-dystroglycan unit. α-dystroglycan 
associates with laminin which in turn associates with the extracellular matrix (not shown) 
(Original Source: e-heart.org, 2009). 
 
The Role of Glycosylation Events  
The role of α-dystroglycan in binding to the extracellular matrix via laminin could 
also be a target path for treatment. Binding to the extracellular matrix is affected by cell 
surface glycosylation of the proteins within the complex. The glycosylation of either 
dystroglycan subunit is modified by genetic changes to that individual subunit.  Binding 
of β-DG to utrophin is associated with specific glycosylation events unique to utrophin 
itself. The utilization of utrophin, rather than dystrophin, correlates with specific 
glycosylation changes on α-DG (Yoon, 2009). Because α-DG can be differentially 
glycosylated, genetically altering these subunit-associated genes can lead to increased 
glycosylation, an event that will promote binding to either laminin or utrophin and 
16 
 
increase stability of the UAGC. An aspect of DMD that contributes to the worsening of 
the disease is the damage caused by muscle contractions. Affected muscle fibers with 
damaged DAGCs and impaired binding are continually weakened by the force of each 
contraction. Better binding will promote increased utrophin and laminin usage by these 
dystroglycan subunits, which will further stabilize the UAGC and reverse the progression 
of DMD pathology.  
The study of the specificity of glycosyltransferase activity identified Galgt2 as the 
glycosyltransferase preferential for the modification of DG binding to utrophin (Nguyen, 
2002). Galgt2 is an N-acetylgalactosamine (GalNAc) saccharide glycosyltransferase. Its 
activity is such that it adds a GalNAc to a premade trisaccharide to make a 
tetrasaccharide-modified α-DG subunit (Cabrera, 2012). This tetrasaccharide 
modification is specific to proteins localized in the neuromuscular junctions and, in turn, 
directly related to utrophin. Because the proteins and assembly of the UAGC have shown 
to be interconnected, overexpression of Galgt2 has shown to not only to increase utrophin 
and laminin binding, but has also contributed to the stability of the complex by increasing 
the amounts of other proteins such as α- and β-DG as well as α-, β-, and γ-SG (Xu, 2009). 
The increase of certain SGs serves to provide additional support in anchoring β-DG 
within the membrane. Furthermore, overexpression of Galgt2 has shown to normalize the 
force of muscle contractions by relieving the strain caused by poor binding within the 
UAGC, increasing and reinforcing the interactions between these proteins and the 
extracellular matrix (Martin, 2009).  The specificity of this glycosylation event suggests 
the possibility of an integration of multiple upregulation therapies unique to utrophin in 




The role of the proteins involved in maintaining muscle fiber structural integrity 
provides the opportunity to incorporate multiple aspects of the UGAC in creating a 
therapy to compensate for the lack of dystrophin. A careful regulation of sarcospan 
overexpression coupled with upregulation of glycosylation activity could rebuild the 
structural integrity of the complex by specifically targeting utrophin interactions and 
binding activity. In terms of tissue specificity, Galgt2 is known to be widely expressed in 
a variety of tissues, including mucosal tissues (Montiel, 2003). This makes it an ideal 
target for systemic gene therapy. A therapy that comprises of a combination between 
highly controlled sarcospan overexpression and Galgt2 glycosyltransferase activity 
upregulation could potentially alleviate DMD pathology and compensate for possible 
problems that could arise from too much overexpression of sarcospan. It would also be 
specific to utrophin-mediated stability, which would eliminate the need for dystrophin-
dependent therapies. The studied effects of Galgt2 glycosylation on the elevated levels of 
sarcoglycans would provide further support of β-DG and, in turn, contribute to stabilizing 
the α-DG subunit in laminin binding. Using viral vectors to transduce expression of these 
proteins in muscle cells seems to be a feasible method of delivery because of the small 
size of both the sarcospan and Galgt2 gene, resolving the obstacle presented by the 
massive size of both utrophin and dystrophin genes. Creating one or several viral vectors 
specific to the overexpression of these proteins and transducing muscle cells with them 





Clinical Case Study 
 
Chief Complaint: Patient “walking clumsily” per mother 
 
HPI: Brandon Stevenson is a 5-year-old white male brought into the clinic by his mother 
with the chief complaint that he is “clumsy when walking.” His difficulties were first 
brought to her attention 6 months ago when his preschool teacher mentioned that he was 
having trouble running around and keeping up with the other kids on the playground. 
Although his 6-year-old sister never had any of these concerns, she attributed it to his 
small size and young age. Since then, however, she has noticed that his clumsiness has 
become more pronounced and he has started to walk somewhat abnormally. He has been 
climbing stairs in a “strange manner,” always using the wall for support and “using only 
one leading leg to climb up.” She doesn’t believe he is feeling any pain, and when asked, 
the patient replied that “nothing hurts” and that his legs are “just tired a lot.” His 
weakness is described as being limited to his lower body, and his mother has noticed that 
his calves are “a little larger than normal,” especially in comparison to his sister. He has 
not fallen or had any head injuries recently. His weakness doesn’t subside with napping 







Past Medical History: Brandon was born vaginally with no complications during 
delivery. His birth weight was 7lbs 2oz. He has shown a normal growth pattern during 
the past five years, though his weight has always been borderline underweight. His most 
recent office visit indicates he has had some minor weight loss. He is prone to ear 
infections, experiencing two in the past year alone. He has not had any surgeries and has 
never been hospitalized. He is not currently taking any medications and is up to date on 
his immunizations. He has received the flu shot recently.  
 
Family History: Both Brandon’s mother and father are in good health with no medical 
concerns. Brandon’s maternal grandmother has type II diabetes. His paternal grandfather 
was a heavy smoker and died from lung cancer at age 64. His paternal uncle died from 
brain cancer at age 22. Brandon’s mother mentioned that her maternal uncle died in his 
early teens from heart complications, but she does not know the exact cause of death. His 
6-year-old sister has never had any problems running and has not experienced any of the 











Social/Sexual History: Brandon lives with his mother, father and 6-year-old sister in 
their new home. They own one family pet, a dog which they have had for 7 years now. 
Brandon began attending an all-day preschool six months ago and has previously 
attended day care since he was two years old. He gets along well with the other children, 
but prefers to spend his free time indoors reading. He has a good relationship with both 
his parents and is very close to his older sister. Brandon has never travelled outside the 
country and has not gone on any trips recently.  His father is a full-time high school 
teacher and his mother is a part-time assistant professor at the local university. Brandon 
has no sexual history. 
 
Allergies/Medications: Brandon is allergic to penicillin. His allergy results in rashes on 
his chest and back as well as itchiness. He uses Children’s Benadryl to treat his 













Review of Systems 
HEENT:  (-) cough or sore throat, (-) ear pain 
Pulmonary: (-) shortness of breath 
Cardiovascular: (-) chest pain 
Abdomen: (-) change in bowel habits 
Musculoskeletal: (-) joint pain, (+) weakness in lower extremities 
Neurological:  (-) headaches, (-) dizziness 
 
Physical Exam Results 
Temperature  = 98.6˚F, ear 
Blood Pressure  = 96/57mmHg 
Pulse   = 84/min 
Respiration  = 23/min 
Height   = 39” 
Weight  = 33 lbs. 
 
General: Slightly underweight male appears healthy but tired.  
 
HEENT:  
Head:    Scalp is smooth and supple with no lesions or areas of tenderness noted. 
Face is symmetrical with no physical abnormalities.  
Eyes:     Pupils are round and equally reactive to light and accommodation.  
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Ears:     Both left and right auditory canals are clear of fluid. The left tympanic 
membrane is pearly grey and intact. Scarring is present in the right ear.  
Nose:    Nose is symmetric and septum is midline. Nasal mucosa is pink and 
moist. No signs of nasal congestion or polyps. 
Throat:  Neck is supple with no tenderness or stiffness. No lymphadenopathy and 
no thyromegaly or nodules were noted.  Lips, tongue, and mucosa are moist and 
pink with no lesions. Tonsils are small with no exudates. 
 
Pulmonary:  Respirations are normal with no signs or respiratory distress. No cough, 
wheezes, or rhonchi present with auscultation. No tenderness of the chest wall elicited on 
exam. 
 
Cardiovascular: Heart rate and rhythm is regular. No murmurs, rubs, or gallops 
auscultated on exam. Radial and pedal pulses were normal. 
 
Abdomen: No swelling or redness of the abdomen and no tenderness with palpitation. 
Bowl sounds present in all 4 quadrants. No masses found.  
 
Musculoskeletal: Fingers and hands appear normal with full range of motion. Spine 
shows signs of lumbar lordosis. Calves appear to be hypertrophied. Patient demonstrates 
difficulty standing up by exhibiting Gower’s sign. Ankle joints appear stiff and he 
demonstrates an abnormal gait at times by walking on his toes. Feet are cold to the touch. 




Neurologic:  Patient is alert. He has normal sensation in all extremities and responds to 
pain and temperature sensations. Deep tendon reflexes are 2+.  
 
 
Laboratory and Imaging Results 
Complete Blood Count with Differential 
RBC Count      4.6 x106/µL 
Hemoglobin      13.2g/dL 
Hematocrit      39.6% 
MCV       86.1fL 
MCH       28.7pg 
MCHC      33.3% 
RDW       13.5% 
WBC Count      7.56 x103/µL 
Neutrophil Count (Absolute)    3.76 x103/µL 
Neutrophil Count (Relative)    49.8% 
Lymphocyte (Absolute)    3.19x103/µL 
Lymphocyte (Relative)    42.2% 
Monocyte Count (Absolute)    0.39 x103/µL 
Monocyte Count (Relative)    5.2% 
Eosinophil Count (Absolute)    0.18 x103/µL 
Eosinophil Count (Relative)    2.4% 
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Basophil Count (Absolute)    0.03 x103/µL 
Basophil Count (Relative)    0.4% 
Platelet Count      380 x103/µL 
MPV       8.6fL 
 
 
Comprehensive Metabolic Panel 
Albumin      4.1g/dL 
Alkaline phosphatase     160 IU/L 
ALT       186 IU/L 
AST        235 IU/L 
BUN        9.6 mg/dL 
Calcium       9.1 mg/dL 
Chloride      102 mmol/L 
CO2       24 mmol/L 
Creatinine       1.01 mg/dL 
Glucose test      86mg/dL 
Potassium test      4.1 mmol/L 
Sodium       141.4 mmol/L 
Total bilirubin       0.9 mg/dL 






TSH       10.23µg/dL 
Free T4      1.2ng/dL 
Free T3      532pg/dL  
 
Serum Creatine Kinase 




Proximal muscles biceps brachii and rectus femoris were tested. An abnormal number of 
small, polyphasic motor unit action potentials were detected. Motor potentials were of 
shorter duration and low amplitude and area. There is a slight decrease of interference 





Muscle biopsy was done on a specimen from the left calf muscle. Variable muscle fiber 
size with some evidence of fiber necrosis. Small amounts of fatty connective tissue 
present. Immunohistostaining reveals no dystrophin present in any of the muscle fibers.  










Figure 4. Immunofluorescence staining for dystrophin in normal and diseased muscle. 
(a) Healthy control muscle with dystrophin present in membrane. (b)Patient muscle 
stained for dystrophin reveals no dystrophin present in membrane (Original Source: 
Petrini et al, 2003). 
 
 
Multiplex Ligation-dependent Probe Amplification Genetic Test 
The dystrophin gene was tested to detect any abnormalities within its various loci. 












Differential Diagnosis: Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, 
neuropathy, hyperthyroidism, electrolyte imbalance, osteomyelitis, anemia  
 
Assessment 
Brandon was brought in with complaints of clumsy walking. Most notably, it was 
seen that he experiences difficulty standing up by exhibiting Gower’s sign and his calves 
appear to be hypertrophied. These observations were classic enough in their presentation 
to suspect muscular dystrophy. However, more benign and common causes of lower limb 
weakness were considered before pursuing a diagnosis of muscular dystrophy. The 
following tests were order to rule out the likelihood of anemia, osteomyelitis, a possibly 
electrolyte imbalance, and hyperthyroidism. 
Brandon’s CBC rules out the possibility of anemia based on normal values for his 
hemoglobin, hematocrit, MCH, MCV, and erythrocyte distribution width. His WBC and 
platelet count are normal and do not necessitate further testing for leukemia or an 
infection, such as osteomyelitis. His comprehensive metabolic panel results revealed 
normal potassium, sodium, and calcium levels. An electrolyte imbalance as a cause of his 
weakness is unlikely based on these results. A standard thyroid panel indicated that he 
has normal levels of TSH, T4, and T3, ruling out hyperthyroidism. His ALT and AST 
were slightly elevated, which could indicate impaired liver function. However, with 
Brandon’s age and symptoms, further evaluation was not pursued at this time as these 




In pursuing a possible diagnosis of Duchenne Muscular Dystrophy, a serum 
creatine kinase test was ordered. Brandon’s serum creatine kinase levels were 
exceptionally elevated, indicating high levels of muscle damage and further supporting 
the suspicion of muscular dystrophy.  An electromyography was ordered to examine the 
state of his muscle contractions. His results of decreased amplitude and duration of motor 
unit action potential as well as an increase in polyphasyic action potentials are 
characteristic of the early phases of DMD. Furthermore, a full interference pattern was 
detected despite a slight decrease in amplitude. These findings, along with normal deep 
tendon reflexes, are not characteristic of a neuropathy, making it an unlikely diagnosis. A 
muscle biopsy of the left calf was done to check the levels of dystrophin. 
Immunohistostaining for dystrophin in the biopsy revealed a complete lack of dystrophin 
in his muscle cells. Based on these results, Duchenne muscular dystrophy is strongly 
suspected as the cause for his symptoms. Because no dystrophin was detected, Becker 
Muscular Dystrophy seems unlikely. Brandon has had normal developmental milestones 
until this point. The sudden onset and progression of his symptoms in these last six 
months from difficulty running around to having difficulty standing up and, upon his 
most recent physical exam, displaying abnormal gait when walking are significant. The 
diagnosis of DMD was confirmed with Multiplex Ligation-dependent Probe 







 Treatment Plan 
Brandon symptoms indicate that he is in the early stages of Duchenne Muscular 
Dystrophy. Research has shown that daily steroid therapy can help slow a decline in 
muscle wasting and even increase muscle strength. It can help reduce the risk of scoliosis 
and stabilize pulmonary function as well as reduce the incidence of cardiomyopathy. 
Brandon is referred to a pediatric neurologist to discuss long-term management of his 
corticoid steroid therapy. He is started on a steroid therapy of 11.25 mg of Prednisone a 
day until his referral goes through, and is scheduled to return in 2 weeks for a follow-up 
on his treatment to assess the effectiveness of the steroid treatment and any side effects 
he may be experiencing. To establish baseline lung function and monitor his long-term 
respiratory management, Brandon is also referred to a pulmonologist.  
For further evaluation of mobility and possible assistance, physical therapy is 
recommended. To maintain functional strength and flexibility, Brandon is referred to a 
physical therapist that has had experience working with DMD patients. Physical therapy 
should help control limb contractures of his lower extremities. Brandon is also 
encouraged to take up swimming or walking to help maintain strength.  
Brandon’s family is also encouraged to make an appointment with a psychologist. 
They are given the names of a few psychologists who specialize in family therapy. They 
are also given information on support groups in the community whose families have been 
affected by DMD.   
The family is referred to a geneticist for further genetic testing to assess the risks 
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